Evidence map›Paper›PMID 38543280›Full record

ArticlePharmaceutics2024

Mesoporous Silica as an Alternative Vehicle to Overcome Solubility Limitations.

Tim Becker, Jan Heitkötter, Anna K Krome, Andrea Schiefer, Kenneth Pfarr, Alexandra Ehrens, Miriam Grosse, Birthe Sandargo, Ingo Stammberger, Marc Stadler and 4 more

Abstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tim BeckerDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany.
Jan HeitkötterDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany.
Anna K KromeDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany.
Andrea SchieferGerman Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany.ORCID 0000-0002-9823-2090
Kenneth PfarrGerman Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany.ORCID 0000-0003-3096-2465
Alexandra EhrensGerman Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany.ORCID 0000-0002-2570-4034
Miriam GrosseDepartment of Microbial Drugs, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany.ORCID 0000-0001-5972-639X
Birthe SandargoDepartment of Microbial Drugs, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany.
Ingo StammbergerToxicological Consulting Services, 65795 Hattersheim am Main, Germany.
Marc StadlerDepartment of Microbial Drugs, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany.ORCID 0000-0002-7284-8671
Marc P HübnerGerman Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany.ORCID 0000-0001-8885-418X
Stefan KehrausGerman Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany.
Achim HoeraufGerman Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany.
Karl G WagnerDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121 Bonn, Germany.ORCID 0000-0003-2864-7191

Funding

Federal Ministry of Education and Research 16GW0227KFederal Ministry of Education and Research 16GW0229German Center for Infection Research TTU 09.822German Center for Infection Research TTU 09.914
6 · The paper itself

Abstract

Toxicological studies are a part of the drug development process and the preclinical stages, for which suitable vehicles ensuring easy and safe administration are crucial. However, poor aqueous solubility of drugs complicates vehicle screening for oral administration since non-aqueous solvents are often not tolerable. In the case of the anti-infective corallopyronin A, currently undergoing preclinical investigation for filarial nematode and bacterial infections, commonly used vehicles such as polyethylene glycol 200, aqueous solutions combined with cosolvents or solubilizers, or aqueous suspension have failed due to insufficient tolerability, solubility, or the generation of a non-homogeneous suspension. To this end, the aim of the study was to establish an alternative approach which offers suitable tolerability, dissolution, and ease of handling. Thus, a corallopyronin A-mesoporous silica formulation was successfully processed and tested in a seven-day toxicology study focused on Beagle dogs, including a toxicokinetic investigation on day one. Sufficient tolerability was confirmed by the vehicle control group. The vehicle enabled high-dose levels resulting in a low-, middle-, and high-dose of 150, 450, and 750 mg/kg. Overall, it was possible to achieve high plasma concentrations and exposures, leading to a valuable outcome of the toxicology study and establishing mesoporous silica as a valuable contender for challenging drug candidates.

Indexed as

corallopyronin Amesoporous silicapoorly soluble drugspreclinical studiestoxicologyvehicle

Identifiers

PMID38543280
PMCPMC10975448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.